Calamos Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Calamos Advisors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.33M	Buy	29,358 +9,577	+48%	+$721K	0.01%	648
2026 Q1	$1.49M	Sell	19,781 -13,408	-40%	-$1.06M	0.01%	716
2025 Q4	$2.63M	Buy	33,189 +7,326	+28%	+$552K	0.01%	597
2025 Q3	$1.69M	Buy	+25,863	New	+$1.26M	0.01%	645
2024 Q1	–	Sell	-16,379	Closed	-$829K	–	989
2023 Q4	$829K	Buy	+16,379	New	+$785K	﹤0.01%	685
2023 Q1	–	Sell	-7,026	Closed	-$265K	–	1173
2022 Q4	$265K	Sell	7,026 -10,093	-59%	-$425K	﹤0.01%	934
2022 Q3	$757K	Buy	+17,119	New	+$721K	﹤0.01%	980
2019 Q3	–	Sell	-3,150	Closed	-$202K	–	772
2019 Q2	$202K	Buy	+3,150	New	+$223K	﹤0.01%	727
2016 Q2	–	Sell	-64,918	Closed	-$2.63M	–	631
2016 Q1	$2.63M	Sell	64,918 -297,107	-82%	-$12.1M	0.02%	413
2015 Q4	$22.4M	Buy	362,025 +223,865	+162%	+$12.1M	0.14%	191
2015 Q3	$5.58M	Hold	138,160	–	–	0.04%	331
2015 Q2	$7.95M	Buy	138,160 +93,630	+210%	+$5.95M	0.05%	308
2015 Q1	$2.83M	Buy	44,530 +37,390	+524%	+$2.54M	0.02%	447
2014 Q4	$441K	Sell	7,140 -7,710	-52%	-$380K	﹤0.01%	613
2014 Q3	$577K	Buy	14,850 +4,700	+46%	+$167K	﹤0.01%	574
2014 Q2	$350K	Buy	+10,150	New	+$320K	﹤0.01%	622

Other funds holding IONS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.32B AUM 32.9% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Calamos Advisors's IONS Position: Q2 2026 in Review

Calamos Advisors increased its Ionis Pharmaceuticals (IONS) stake by 48% in Q2 2026, buying an estimated $721K and bringing the position to 29,358 shares worth $2.33M. The position accounts for 0.01% of the portfolio, ranked #648.

Calamos Advisors first reported a position in IONS in Q2 2014 and has held it in 16 quarters since. The position peaked at $22.4M in Q4 2015. 218 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Calamos Advisors held 29,358 shares of Ionis Pharmaceuticals worth $2.33M as of Q2 2026.
Calamos Advisors bought 9,577 Ionis Pharmaceuticals shares in Q2 2026, an estimated $721K.
Ionis Pharmaceuticals made up 0.01% of Calamos Advisors's portfolio in Q2 2026, its #648 holding.
Calamos Advisors first reported a position in Ionis Pharmaceuticals in Q2 2014 and has held it in 16 quarters since.
Calamos Advisors's Ionis Pharmaceuticals position peaked at $22.4M in Q4 2015.
218 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.